EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Axitinib in Metastatic Renal Cell Carcinoma

Kriti Mittal, Laura S Wood, Brian I Rini

Biologics in Therapy · 2012

DOI: 10.1007/s13554-012-0005-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biologics in Therapy, 2012. Verfasst von Kriti Mittal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Taussig Cancer Institute, 9500 Euclid Avenue Desk R 35, 44195 Cleveland, Ohio USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted agents have revolutionized the management of metastatic renal cell carcinoma (RCC). Axitinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), has been an important addition to currently available therapies for advanced RCC. Its ability to inhibit VEGFRs at nanomolar concentrations distinguishes it as a potent tyrosine kinase inhibitor, with increased selectivity for VEGFR-1, 2, and 3 at clinically applicable concentrations. The phase 3 AXIS trial has established its superiority in prolonging progression-free survival (PFS) in previously treated RCC patients (median PFS 6.7 months for axitinib vs. 4.7 months for sorafenib). Common toxicities of axitinib include hypertension, diarrhea, nausea, hand-foot syndrome, fatigue, and hypothyroidism. Axitinib-induced diastolic blood pressure elevation may be associated with improved clinical outcome, likely reflecting the "on-target" effect of axitinib. Dose escalation to achieve therapeutic plasma drug levels is of considerable clinical interest. Although axitinib has established efficacy in patients treated with one previous agent, its use in the frontline setting is currently the subject of ongoing research.

Schlagwörter

Stichwörter der Autor:innen

Advanced renal cell carcinomaAxitinibOncologyPharmacodynamicsProgression-free survivalVascular endothelial growth factor receptor

Autor:innen und Institutionen

  • Cleveland Clinic, Taussig Cancer Institute, 9500 Euclid Avenue Desk R 35, 44195 Cleveland, Ohio USA.

Zitieren

APA

Mittal, K., Wood, L. S., & Rini, B. I. (2012). Axitinib in Metastatic Renal Cell Carcinoma. Biologics in Therapy. https://doi.org/10.1007/s13554-012-0005-2

Vancouver

Mittal K, Wood LS, Rini BI. Axitinib in Metastatic Renal Cell Carcinoma. Biologics in Therapy. 2012. doi:10.1007/s13554-012-0005-2

BibTeX
@article{Mittal2012,
  author = {Mittal, Kriti and Wood, Laura S and Rini, Brian I},
  title = {Axitinib in Metastatic Renal Cell Carcinoma},
  journal = {Biologics in Therapy},
  year = {2012},
  doi = {10.1007/s13554-012-0005-2}
}
Kostenlos starten →